EXTH-52. EGFRvIII: A NEW PREDICTIVE BIOMARKER FOR TEMOZOLOMIDE RESPONSE IN MGMT PROMOTOR METHYLATED GLIOBLASTOMA PATIENTS

Despite many clinical efforts, the prognosis of GBM patients has not improved in the last 10 years. Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene is the only predictive biomarker that is associated with temozolomide (TMZ) response. The establishment of new biomarkers...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Struve, Nina, Brend, Tim, Stead, Lucy, Binder, Zev A, Ott, Leonie, Muller-Goebel, Justus, Hoffer, Konstatin, Morrissette, Jennifer J D, Petersen, Cordula, Rothkamm, Kai, O’Rourke, Donald, Short, Susan C, Kriegs, Malte
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.344
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller